NovoCure Limited (NVCR)
| Market Cap | 2.83B |
| Revenue (ttm) | 577.74M |
| Net Income (ttm) | -149.78M |
| Shares Out | 108.20M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,156,083 |
| Open | 25.99 |
| Previous Close | 26.02 |
| Day's Range | 25.66 - 27.11 |
| 52-Week Range | 11.70 - 34.13 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 33.40 (+27.63%) |
| Earnings Date | Feb 27, 2025 |
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporate... [Read more]
Financial Performance
In 2023, NovoCure's revenue was $509.34 million, a decrease of -5.30% compared to the previous year's $537.84 million. Losses were -$207.04 million, 123.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $33.4, which is an increase of 27.63% from the latest price.
News
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update.
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference.
NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer
NovoCure's TTFields therapy, combined with standard chemotherapy, significantly improves overall survival in advanced pancreatic cancer, showing a 33% improvement in two-year survival rates. Despite p...
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory sub...
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxe...
Novocure's pancreatic cancer treatment meets main goal in late-stage study
Novocure said on Monday its experimental therapy extended the lives of patients with a form of advanced pancreatic cancer when combined with chemotherapy, achieving the primary goal in a late-stage tr...
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met it...
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer.
Novocure to Participate in Upcoming Investor Conferences
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to participate in upcoming investor conferences.
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure data at 2024 SNO annual meeting highlights product innovation and real-world evidence for TTFields therapy in glioblastoma.
FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--FDA approves Novocure's Innovative HFE transducer arrays for use with Optune Gio® for glioblastoma.
NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript
NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Fr...
Novocure Appoints Christoph Brackmann as Chief Financial Officer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Appoints Christoph Brackmann as Chief Financial Officer.
Novocure Reports Third Quarter 2024 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Third Quarter 2024 Financial Results.
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top...
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
On Tuesday, the FDA approved NovoCure's NVCR Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progr...
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhib...
Novocure to Report Third Quarter 2024 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open.
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Present Real-World Data at ESMO 2024.
Novocure Announces Planned CEO Transition
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Planned CEO Transition.
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2024 Wells Fargo Healthcare Conference.
Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced its participation in the upcoming International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
Biotech stocks: Which drugmakers are worth a buy?
While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation...
NovoCure Limited: A Post Q2 Analysis
Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarte...
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and ...